FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum

Importantly, the study saw few cases of hyperkalemia associated with the drug, suggesting it avoids a major problem associated with spironolactone and eplerenone.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news